Open Access Articles- Top Results for Ciclesonide


File:Ciclesonide ball-and-stick animation.gif
Systematic (IUPAC) name
2-[(1S, 2S, 4R, 8S, 9S,11S, 12S, 13R)-6-cyclohexyl-11-hydroxy-9, 13-dimethyl-16-oxo-5, 7-dioxapentacyclo [,9.04, 8.013,18] icosa-14, 17-dien-8-yl]- 2-oxoethyl 2-methylpropanoate
Clinical data
AHFS/ monograph
MedlinePlus a607008
  • AU: B3
  • US: C (Risk not ruled out)
nasal inhalation
141845-82-1 7pxY
R01AD13 R03BA08
PubChem CID 6918155
DrugBank DB01410 7pxY
ChemSpider 5293368 7pxY
UNII S59502J185 7pxY
KEGG D01703 7pxY
ChEMBL CHEMBL1201164 7pxN
Synonyms (11β, 16α)-16, 17-[[(R)-cyclohexylmethylene]bis(oxy)]-11-hydroxy-21- (2-methyl-1-oxopropoxy)- pregna-1, 4-diene-3, 20-dione
Chemical data
Formula C32H44O7
540.688 g/mol
 14pxN (what is this?)  (verify)

Ciclesonide is a glucocorticoid used to treat asthma and allergic rhinitis. It is marketed under the brand name Alvesco for asthma and Omnaris/Omniair for hay fever in the US and Canada. Phase 3 trials for the hay fever indication outside the US are ongoing.[1] The drug was approved for adults and children 12 and over by the US Food and Drug Administration in October 2006.[2] Side effects of the medication include headache, nosebleeds, and inflammation of the nose and throat linings.[3]


  1. ^ "OMNARIS/OMNAIR". Products. Nycomed International Management GmbH. 2009. Retrieved 2009-07-30. [dead link]
  2. ^ "FDA NEWS RELEASE. FDA Approves New Treatment for Allergies.". Food and Drug Administration. 2006-10-23. Retrieved 2009-07-30. 
  3. ^ Mutch, Elaine; Nave, Ruediger; McCracken, Nigel; Zech, Karl; Williams, Faith M. (2007). "The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue". Biochemical Pharmacology 73 (10): 1657–64. PMID 17331475. doi:10.1016/j.bcp.2007.01.031. 
  • Rossi S (Ed.) (2006). Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook. ISBN 0-9757919-2-3